
-
US projected to hit debt limit in August: Treasury chief
-
'You're gonna be the Pope,' Leo XIV's brother recalls telling him
-
Guardiola says Man City season has been toughest in management
-
'It's terrific': Chicago hails hometown hero Pope Leo XIV
-
Europe leaders head to Kyiv on unprecedented visit
-
Pakistan warns won't de-escalate as conflict with India spirals
-
Stocks mixed as global markets eye US-China tariff talks
-
Serbia's Vucic seeks low-price gas in Putin meeting
-
German Holocaust survivor and witness-bearer Margot Friedlaender dies at 103
-
Timberwolves launch probe after fan's 'racially charged' abuse
-
Giro over for Landa after high-speed opening stage crash
-
US approves first at-home cervical cancer screening device
-
FIFA Women's World Cup expanded to 48 teams from 2031
-
Mitchell leads, Lowry charges and Rory five back at rainy Truist
-
Gauff holds nerve to join Sabalenka in Italian Open third round
-
Israel not involved in Gaza food distribution under US aid plan: envoy
-
Margot Friedlaender, Germany's voice of Holocaust remembrance
-
Fallen giant Hamburg close in on top-flight redemption
-
Dozens of minors killed in Mexico cartel infighting
-
Trump fires librarian of US Congress
-
Spurs will show no fear against Man Utd in Europa League final: Van de Ven
-
Renowned Holocaust survivor Margot Friedlaender dies at 103
-
Woods, 16-year-old Charlie, misses out in US Open qualifier
-
Pakistan says India has put neighbours 'closer to major conflict'
-
On patrol for jihadists with Mauritania's camel cavalry
-
France, Poland sign treaty with mutual defence pledge
-
NATO chief seeks defence spending at 5% of GDP by 2032: Dutch PM
-
La Rochelle head coach O'Gara suspended for five weeks
-
Measles roars back in the US, topping 1,000 cases
-
Fulham boss Silva refuses to rule out Saudi switch
-
From Chicago to Chiclayo: Peruvian town hails adoptive son and pope
-
Ivorian women fight FGM with reconstructive surgery
-
Pedersen wins opening stage of Giro d'Italia in Albania
-
Stocks mixed despite hopes for US-China tariff talks
-
US, Swiss agree to speed up tariff talks
-
Trump floats cutting China tariffs to 80% ahead of trade talks
-
Pedersen wins opening stage of Giro d'Italia
-
Marc Marquez sets Le Mans lap record in French MotoGP practice
-
Jungle music: Chimp drumming reveals building blocks of human rhythm
-
Guardiola tells Man City stars to question their hunger after troubled season
-
Putin, Xi, Steven Seagal and missiles: Russia's Red Square parade
-
Trump suggests lower 80% China tariff ahead of Geneva trade talks
-
Arteta wants Arsenal to use Liverpool guard of honour as title fuel
-
Stocks lifted by hopes for US-China talks
-
Putin hails troops in Ukraine as allies attend WWII parade
-
UK, northern European nations support Ukraine 30-day ceasefire: Norway PM
-
Activists hold 'die-in' protest at Soviet monument in Warsaw
-
Trump suggests lower China tariff, says 80% 'seems right!'
-
Alonso confirms exit from Leverkusen at end of season
-
Maresca ready for Chelsea's 'huge' Newcastle test

Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
L.Mason--AMWN